PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Approves share buyback of up to $50 million. Programme follows ‘follows consultation with shareholders and is consistent with PureTech’s capital allocation strategy and stated approach to drive additional value for its shareholders,’ company says. PureTech says it had $413.2 million of net cash and cash equivalents at March 31. Given size of balance sheet, PureTech is confident it can return capital to shareholders and also maintain ‘sufficient cash on hand to deliver’ on strategic priorities.

Current stock price: 186.14 pence, up 11%

12-month change: down 53%

Copyright 2022 Alliance News Limited. All Rights Reserved.